Report Detail
Global (United States, European Union and China) Rivastigmine Oral Market Research Report 2019-2025
- RnM3675212 |
- 16 August, 2019 |
- Global |
- 118 Pages |
- QYResearch |
- Pharma & Healthcare
Rivastigmine (sold under the trade name Exelon) is a acetylcholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and Parkinson's. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.
In 2019, the market size of Rivastigmine Oral is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Rivastigmine Oral.
This report studies the global market size of Rivastigmine Oral, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Rivastigmine Oral sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Novartis
Sun Pharmaceutical
Mylan Pharmaceuticals
Teva
Dr. Reddy's Laboratories
Orchid Healthcare
APOTEX
Alembic Pharmaceuticals
MACLEODS
Cadila Pharmaceuticals
Aurobindo Pharma
Ajanta Pharma
Market Segment by Product Type
1.5 mg Capsules
3 mg Capsules
4.5 mg Capsules
6 mg Capsules
2mg/ml Oral solution
Market Segment by Application
Alzheimer's disease
Parkinson's
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Rivastigmine Oral status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Rivastigmine Oral manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Rivastigmine Oral are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Rivastigmine Oral Market Size Growth Rate by Type (2019-2025)
- 1.3.2 1.5 mg Capsules
- 1.3.3 3 mg Capsules
- 1.3.4 4.5 mg Capsules
- 1.3.5 6 mg Capsules
- 1.3.6 2mg/ml Oral solution
- 1.4 Market Segment by Application
- 1.4.1 Global Rivastigmine Oral Market Share by Application (2019-2025)
- 1.4.2 Alzheimer's disease
- 1.4.3 Parkinson's
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Rivastigmine Oral Market Size
- 2.1.1 Global Rivastigmine Oral Revenue 2014-2025
- 2.1.2 Global Rivastigmine Oral Sales 2014-2025
- 2.2 Rivastigmine Oral Growth Rate by Regions
- 2.2.1 Global Rivastigmine Oral Sales by Regions 2014-2019
- 2.2.2 Global Rivastigmine Oral Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Rivastigmine Oral Sales by Manufacturers
- 3.1.1 Rivastigmine Oral Sales by Manufacturers 2014-2019
- 3.1.2 Rivastigmine Oral Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Rivastigmine Oral Revenue by Manufacturers (2014-2019)
- 3.2.2 Rivastigmine Oral Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Rivastigmine Oral Market Concentration Ratio (CR5 and HHI)
- 3.3 Rivastigmine Oral Price by Manufacturers
- 3.4 Key Manufacturers Rivastigmine Oral Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Rivastigmine Oral Market
- 3.6 Key Manufacturers Rivastigmine Oral Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 1.5 mg Capsules Sales and Revenue (2014-2019)
- 4.1.2 3 mg Capsules Sales and Revenue (2014-2019)
- 4.1.3 4.5 mg Capsules Sales and Revenue (2014-2019)
- 4.1.4 6 mg Capsules Sales and Revenue (2014-2019)
- 4.1.5 2mg/ml Oral solution Sales and Revenue (2014-2019)
- 4.2 Global Rivastigmine Oral Sales Market Share by Type
- 4.3 Global Rivastigmine Oral Revenue Market Share by Type
- 4.4 Rivastigmine Oral Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Rivastigmine Oral Sales by Application
6 United States
- 6.1 United States Rivastigmine Oral Breakdown Data by Company
- 6.2 United States Rivastigmine Oral Breakdown Data by Type
- 6.3 United States Rivastigmine Oral Breakdown Data by Application
7 European Union
- 7.1 European Union Rivastigmine Oral Breakdown Data by Company
- 7.2 European Union Rivastigmine Oral Breakdown Data by Type
- 7.3 European Union Rivastigmine Oral Breakdown Data by Application
8 China
- 8.1 China Rivastigmine Oral Breakdown Data by Company
- 8.2 China Rivastigmine Oral Breakdown Data by Type
- 8.3 China Rivastigmine Oral Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Rivastigmine Oral Breakdown Data by Company
- 9.2 Rest of World Rivastigmine Oral Breakdown Data by Type
- 9.3 Rest of World Rivastigmine Oral Breakdown Data by Application
- 9.4 Rest of World Rivastigmine Oral Breakdown Data by Countries
- 9.4.1 Rest of World Rivastigmine Oral Sales by Countries
- 9.4.2 Rest of World Rivastigmine Oral Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Novartis
- 10.1.1 Novartis Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Rivastigmine Oral
- 10.1.4 Rivastigmine Oral Product Introduction
- 10.1.5 Novartis Recent Development
- 10.2 Sun Pharmaceutical
- 10.2.1 Sun Pharmaceutical Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Rivastigmine Oral
- 10.2.4 Rivastigmine Oral Product Introduction
- 10.2.5 Sun Pharmaceutical Recent Development
- 10.3 Mylan Pharmaceuticals
- 10.3.1 Mylan Pharmaceuticals Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Rivastigmine Oral
- 10.3.4 Rivastigmine Oral Product Introduction
- 10.3.5 Mylan Pharmaceuticals Recent Development
- 10.4 Teva
- 10.4.1 Teva Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Rivastigmine Oral
- 10.4.4 Rivastigmine Oral Product Introduction
- 10.4.5 Teva Recent Development
- 10.5 Dr. Reddy's Laboratories
- 10.5.1 Dr. Reddy's Laboratories Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Rivastigmine Oral
- 10.5.4 Rivastigmine Oral Product Introduction
- 10.5.5 Dr. Reddy's Laboratories Recent Development
- 10.6 Orchid Healthcare
- 10.6.1 Orchid Healthcare Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Rivastigmine Oral
- 10.6.4 Rivastigmine Oral Product Introduction
- 10.6.5 Orchid Healthcare Recent Development
- 10.7 APOTEX
- 10.7.1 APOTEX Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Rivastigmine Oral
- 10.7.4 Rivastigmine Oral Product Introduction
- 10.7.5 APOTEX Recent Development
- 10.8 Alembic Pharmaceuticals
- 10.8.1 Alembic Pharmaceuticals Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Rivastigmine Oral
- 10.8.4 Rivastigmine Oral Product Introduction
- 10.8.5 Alembic Pharmaceuticals Recent Development
- 10.9 MACLEODS
- 10.9.1 MACLEODS Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Rivastigmine Oral
- 10.9.4 Rivastigmine Oral Product Introduction
- 10.9.5 MACLEODS Recent Development
- 10.10 Cadila Pharmaceuticals
- 10.10.1 Cadila Pharmaceuticals Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Rivastigmine Oral
- 10.10.4 Rivastigmine Oral Product Introduction
- 10.10.5 Cadila Pharmaceuticals Recent Development
- 10.11 Aurobindo Pharma
- 10.12 Ajanta Pharma
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Rivastigmine Oral Sales Channels
- 11.2.2 Rivastigmine Oral Distributors
- 11.3 Rivastigmine Oral Customers
12 Market Forecast
- 12.1 Global Rivastigmine Oral Sales and Revenue Forecast 2019-2025
- 12.2 Global Rivastigmine Oral Sales Forecast by Type
- 12.3 Global Rivastigmine Oral Sales Forecast by Application
- 12.4 Rivastigmine Oral Forecast by Regions
- 12.4.1 Global Rivastigmine Oral Sales Forecast by Regions 2019-2025
- 12.4.2 Global Rivastigmine Oral Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Rivastigmine Oral. Industry analysis & Market Report on Rivastigmine Oral is a syndicated market report, published as Global (United States, European Union and China) Rivastigmine Oral Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Rivastigmine Oral market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
